← Back to Search

Stem Cell Transplantation

HPC, Cord Blood for Stroke

Phase 1
Waitlist Available
Led By Brian Mehling, MD
Research Sponsored by BHI Therapeutic Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months post first administration
Awards & highlights

Study Summary

This study is evaluating whether a treatment of cord blood cells may help individuals who have had a stroke.

Eligible Conditions
  • Stroke

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months post first administration
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months post first administration for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events
Graft Versus Host Disease
Secondary outcome measures
Change in Barthel Index
Change in Infarct Volumes measured by Magnetic Resonance Imaging
Change in National Institutes of Health Stroke Scale
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: HPC, Cord BloodExperimental Treatment1 Intervention
HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10^8 total nucleated cells with a minimum of 1.25 × 10^6 viable CD34+ cells in a volume of 25 milliliters.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HPC, Cord Blood
2000
Completed Phase 2
~3630

Find a Location

Who is running the clinical trial?

BHI Therapeutic SciencesLead Sponsor
Brian Mehling, MDPrincipal InvestigatorBHI Therapeutic Sciences

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke
Brian Mehling 2021. "Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03735277.
All > Anterior Ischemic Optic Neuropathy
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top